TY - JOUR
T1 - The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus.
AU - Jenkins, Erin T.
AU - Jensen, Donald M.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2012/12
Y1 - 2012/12
N2 - An increased understanding of viral kinetics has allowed clinicians to tailor therapy for hepatitis C virus through identifying patients who have the best chance of viral eradication and those for whom therapy will likely fail. Nonetheless, sustained viral response rates with pegylated interferon (PegIFN) and ribavirin remain disappointingly low. However, exciting advancements in the field of hepatitis C therapy include the development of new direct-acting antiviral agents, which offer much higher rates of sustained viral eradication when used in combination with PegIFN and ribavirin.
AB - An increased understanding of viral kinetics has allowed clinicians to tailor therapy for hepatitis C virus through identifying patients who have the best chance of viral eradication and those for whom therapy will likely fail. Nonetheless, sustained viral response rates with pegylated interferon (PegIFN) and ribavirin remain disappointingly low. However, exciting advancements in the field of hepatitis C therapy include the development of new direct-acting antiviral agents, which offer much higher rates of sustained viral eradication when used in combination with PegIFN and ribavirin.
UR - http://www.scopus.com/inward/record.url?scp=84876450432&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876450432&partnerID=8YFLogxK
U2 - 10.1016/j.idc.2012.08.007
DO - 10.1016/j.idc.2012.08.007
M3 - Review article
C2 - 23083821
AN - SCOPUS:84867685800
VL - 26
SP - 879
EP - 891
JO - Infectious Disease Clinics of North America
JF - Infectious Disease Clinics of North America
SN - 0891-5520
IS - 4
ER -